Compare Inovio Pharmaceuticals Inc (INO) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Paychex, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Paychex, Inc. trades at $120.12 (market cap $43.14B). The key difference: Paychex, Inc. is far larger — about 549.2× Inovio Pharmaceuticals Inc's market cap, and Paychex, Inc. pays a 3.92% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PAYX | |
|---|---|---|
Market Cap | $78.55M | $43.14B |
Sector | Health | Industrials |
52-Week High | $2.87 | $140.81 |
52-Week Low | $0.66 | $85.57 |
Enterprise Value | $49.56M | $46.63B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Paychex (PAYX) trades at $121.18, up 0.95% with a bullish technical outlook and strong fundamentals. The company maintains robust profitability with 27.03% net margins and consistent earnings beats. Recent expansion of WISE platform and steady small business employment trends support growth. Technical indicators show bullish momentum with support at $120 and resistance at $122.
PAYX offers stable dividend income and consistent execution but faces valuation concerns with P/E of 24.81 above sector averages. Analyst consensus remains cautious with 63% hold ratings. Key risks include economic sensitivity and competitive pressures in HR services. Upside depends on continued market share gains and margin maintenance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
